Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633017 · ClinicalTrials.gov registry record
Breathing With a Facemask Exercise Performance
A clinical trial, sponsored by CereVu Medical.
- Completed
- Registry status
- 52
- Enrollment target
NCT05633017: Completed study, sponsored by CereVu Medical.
NCT05633017 is a clinical trial that has completed, run by CereVu Medical. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05633017 has completed, sponsored by CereVu Medical.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
This study will determine the dyspnea response in chronic lung disease volunteers during treadmill walking with and without added inspiratory resistance. This study will also determine the level of dyspnea and exercise sense of effort in individuals walking on a treadmill when elevations occur. Comparisons will be made of a participant's exercise response with and without increased inspiratory resistance. In this study, exercise performance will be analyzed based on physiological and perceptual measures. The participant will undergo two sessions: one session will be a standard exercise walking test without an inspiratory resistance; the other session will be the same standard exercise walking test while breathing with an inspiratory resistance equal to a N95 facemask (R=10-15 cmH2O/L/sec). Performance will be determined by physiological measures. Perception will be determined by scores based on numerical scales and automatically with the forehead Vitality remote monitoring sensor.
Interventions
- COMBINATION_PRODUCT CereVu Objective Dyspnea Score
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2024-09-17 |
What the finished NCT05633017 record still lists
NCT05633017 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CereVu Objective Dyspnea Score is the first listed.
NCT05633017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05633017 about?
NCT05633017 is a clinical study titled "Breathing With a Facemask Exercise Performance". This study will determine the dyspnea response in chronic lung disease volunteers during treadmill walking with and without added inspiratory resistance. This study will also determine the level of dyspnea and exercise sense of effort in individuals walking on a treadmill when elevations occur. Comp...
What is the current status of trial NCT05633017?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2022-11-29. Estimated completion is 2024-09-17.
What interventions are being tested in trial NCT05633017?
The interventions under investigation include: CereVu Objective Dyspnea Score (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05633017?
This trial is sponsored by CereVu Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI